FDA Approves Wezlana for Multiple Inflammatory Diseases
By Lori Solomon HealthDay Reporter
THURSDAY, Nov. 2, 2023 -- The U.S. Food and Drug Administration has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.
The approval includes indications for adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn disease, and moderately to severely active ulcerative colitis. Additionally, the approval includes indications for pediatric patients (aged 6 years and older) with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy and those with active psoriatic arthritis.
Approval of Wezlana was based on a review of scientific evidence that showed it is highly similar to Stelara in terms of safety, purity, and potency. Evidence from chemical and biological tests and biological assays confirmed similarity in the structural and functional features of Wezlana and Stelara (including those known to impact safety and efficacy). Additionally, evidence included comparative human pharmacokinetic data, clinical immunogenicity data, and other clinical safety and effectiveness data. Infection is the most serious known side effect in both drugs.
"Biosimilar medications offer additional safe and effective treatment options that have the potential to increase access for people requiring treatment for inflammatory diseases," Nikolay Nikolov, M.D., from the FDA Center for Drug Evaluation and Research, said in a statement. "Today's approval could have a meaningful impact for patients managing their disease."
Approval of Wezlana was granted to Amgen.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Evidence-Based Approach Recommended for Acute Pancreatitis Management
MONDAY, March 18, 2024 -- In a clinical guideline issued by the American College of Gastroenterology and published online in the March issue of the American Journal of...
One Hundred Seventeen Cases of MIS-C Identified During 2023
THURSDAY, March 14, 2024 -- In 2023, 117 cases of multisystem inflammation syndrome in children (MIS-C) were reported, with 26 percent of patients having onset during August to...
Rheumatology Workforce Increased 20 Percent From 2009 to 2019
THURSDAY, March 14, 2024 -- The overall number of clinically active rheumatology providers grew more than 20 percent during the last decade, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.